企业QQ
官方微信
| 货号： | cliocell |
Who we are...
Part of the Pharmacells™ group of companies and brands, we are experts in the invention, development and commercialisation of new biotechnology and life sciences products.
Our product range is multi-patented and available all over the world.
We are based in the United Kingdom and operate from our own, fully UK regulatory compliant laboratory facilities.
We work to cGMP standards under Human Tissue Authority Licence no. 22622 and are therefore fully compliant with the EUCTD - European Cells and Tissues Directives.
What we do...
Our in-house team of experienced scientists work in collaboration with some of the worlds most respected institutions and biotechnology firms to create new products, particularly in the cell biology space.
Were most well-known for our Oristem® adult stem cell banking product range which is revolutionising the way that stem cells are stored for adults around the world.
We also work with stem cells to develop new types of personalised cell therapies and it is that work that lead us to find new ways to improve cell viability.
How were different...
We have taken a concept that is well-known (magnetic separation) but that had only demonstrated variable quality results and made it more reliable and feasible for use within modern science.
Product development took place in the UK over a number of years and has culminated in a simple, cost-effective process that opens up debris removing nanotechnology to all.
We have companies big and small, academic institutions, research institutions and government/fedaral agancies using our product to improve their work every day.
Drop us a line and we can tell you a little more about who uses the products and how we have helped improve their project outcomes.
Our Science
ClioCell™ is an ex-vivo device for removal of dying and dead cells, improving viability and quality of cell populations and their subsequent productivity. The system comprises super-paramagnetic nanoparticles which have been coupled with proprietary elements that bind to dead and dying cells and cell debris. The resultant product selectively initiates dead-cell removal, emulating dead-cell clearance mechanisms which operate in-vivo to keep tissues functioning optimally. This technology is step-changing, providing new opportunities to optimise cell growth, culture and storage.
ClioCell™has a broad array of uses, spanning a number of diverse academic and industrial applications. The ability to selectively remove inhibitory or toxic dead cells using a simple and rapid procedure results in radically improved cell populations; specifically, with regard to viability antibody/protein yield and consequent functional efficacy.
If you have a bespoke application, please use the contact us section to get in touch and discuss your requirements. Cliocell™ can be manufactured to cGMP grade and our team has experience of many cell types, pre and post thaw applications and "Big Pharma" project work.